ASPET

AUGUST 10, 2023

In cell-based assays, pegozafermin had a similar receptor engagement profile as native FGF21, with approximately 8-fold higher potency at FGF receptor 1 (FGFR1). Pharmacokinetic half-lives ranged from 55 to 100 hours over the clinically relevant dose range, consistent with the expected half-life extension by glycoPEGylation.

Cell Based Assays 100

Cell Based Assays Pharmacokinetics Regulations Treatment 100

DrugBank

FEBRUARY 12, 2025

This approach capitalizes on prior investments in R&D, mitigates risk by leveraging established safety and pharmacokinetic profiles, and accelerates the delivery of treatments to patients. Key techniques include high-throughput screening (HTS), cell-based assays, and animal models.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

Molecular Design

MARCH 26, 2024

For example, we might examine the structure-activity relationship in a cell-based assay for consistency with the structure-activity relationship that we’ve observed in the enzyme inhibition assay. We have to make assumptions in these situations and we also need to check that these assumptions are reasonable.

Drugs 60

Drugs Pharmacokinetics Cell Based Assays Treatment 60

Alta Sciences

SEPTEMBER 27, 2024

As the complexity of these therapeutics increases, so must the sophistication of the bioanalytical assays designed to either quantify them or measure their impact on the patient. This includes careful consideration of pharmacokinetic and pharmacodynamic endpoints , as well as regulatory and bioanalytical requirements.

Clinical Trials 52

Clinical Trials Trials Pharmacokinetics Small Molecule 52